Venture capitalists mitigate the exceptional scientific, regulatory, and market risks of early-stage life sciences through contractual governance that shapes control, information flow, and milestone discipline. These covenants aim to protect capital while aligning incentives for long, uncertain development paths typical of drug and platform companies.
Financial and control covenants
VCs routinely use preferred equity instruments with liquidation preferences, anti-dilution protections, and dividend mechanics to secure downside protection. Paul Gompers Harvard Business School and Josh Lerner Harvard Business School document that preferred securities and explicit payout priorities are central to venture contracting because they reallocate risk between founders and investors. Board composition and reserved matters grant board seats and veto rights over hiring, further financing, and strategic exits; Steven N. Kaplan University of Chicago Booth School shows these control levers reduce agency problems by enabling active oversight. Staged financing tied to scientific or regulatory milestones imposes discipline on cash burn while allowing investors to reassess value as clinical data emerge.Operational, intellectual property, and regulatory covenants
Contracts frequently require robust IP assignment and warranty clauses, licensing approvals, and covenants to maintain patent prosecution. Rebecca Eisenberg University of Michigan emphasizes the centrality of intellectual property in biotech valuation and the need for clear ownership of inventions. Information rights and auditing provisions give investors regular access to trial data, budgets, and regulatory filings. Step-in or replacement rights enable investors to change management or pursue licensing if the company stalls. Regulatory realities governed by the Food and Drug Administration create covenants around compliance, reporting, and use of funds for clinical development; the long regulatory horizon drives both conservatism and close monitoring.Consequences of these covenants include accelerated professionalization of management and strong investor influence on strategic choices, which can speed development but may also constrain founders’ autonomy and shape research priorities toward exit-ready products. In regional ecosystems such as Boston and San Francisco, intense investor oversight has helped concentrate expertise and facilities, affecting local labor markets and collaboration cultures. Ethically and socially, tighter governance can protect patient safety by enforcing regulatory standards, yet it can also prioritize commercially viable indications over neglected diseases. The net effect is a trade-off between enabling risky, capital-intensive innovation and channeling it through investor-driven governance structures.